Accolade Inc (NAS:ACCD)

$ 7.16 -0.07 (-0.97%) Market Cap: 561.03 Mil Enterprise Value: 571.13 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 75/100

Q4 2024 Accolade Inc Earnings Call Transcript
Apr 25, 2024

$9.19 (-2.23%)

Earnings
Accolade Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2024 Accolade Inc Earnings Call Transcript
Jan 08, 2024

$11.62 (+4.31%)

Earnings
Q2 2024 Accolade Inc Earnings Call Transcript
Oct 04, 2023

$9.75 (-3.56%)

Earnings
Accolade Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q1 2024 Accolade Inc Earnings Call Transcript
Jun 29, 2023

$12.64 (+0.24%)

Earnings
Accolade Inc at Stifel Cross Sector Insight Conference Transcript
Jun 06, 2023
Accolade Inc at Bank of America Global Healthcare Conference Transcript
May 09, 2023
Accolade Inc Investor Day Transcript
May 08, 2023
Q4 2023 Accolade Inc Earnings Call Transcript
Apr 27, 2023

$16.06 (+0.37%)

Earnings
Q3 2023 Accolade Inc Earnings Call Transcript
Jan 09, 2023

$7.74 (+4.17%)

Earnings
Q2 2023 Accolade Inc Earnings Call Transcript
Oct 06, 2022

$12.39 (-0.72%)

Earnings
Accolade Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q1 2023 Accolade Inc Earnings Call Transcript
Jun 30, 2022

$7.4 (-7.85%)

Earnings
Accolade Inc at Bank of America Healthcare Conference Transcript
May 12, 2022
Q4 2022 Accolade Inc Earnings Call Transcript
Apr 28, 2022

$11.06 (-9.93%)

Earnings
Q3 2022 Accolade Inc Earnings Call Transcript
Jan 10, 2022

$19.14 (-8.51%)

Earnings
Accolade Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2021
Q2 2022 Accolade Inc Earnings Call Transcript
Oct 07, 2021

$39.93 (-0.42%)

Earnings
Accolade Inc At EVOLVE Q&A Call Transcript
Sep 21, 2021
Accolade Inc At EVOLVE Keynote Call Transcript
Sep 21, 2021
Accolade Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q1 2022 Accolade Inc Earnings Call Transcript
Jul 08, 2021

$52.36 (-1.04%)

Earnings
Accolade Inc at Stifel Cross Sector Insight Conference (Virtual) Transcript
Jun 10, 2021
Accolade Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Accolade Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 12, 2021
Q4 2021 Accolade Inc Earnings Call Transcript
May 05, 2021

$45.05 (-2.51%)

Earnings
Accolade Inc Acquisition of PlushCare Inc M&A Call Transcript
Apr 23, 2021
Accolade Inc to Acquire 2nd.MD Transcript
Jan 14, 2021
Accolade Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Q3 2021 Accolade Inc Earnings Call Transcript
Jan 07, 2021

$46.92 (+6.52%)

Earnings
Accolade Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 11, 2020
Q2 2021 Accolade Inc Earnings Call Transcript
Oct 14, 2020

$44.49 (+1.23%)

Earnings
Q1 2021 Accolade Inc Earnings Call Transcript
Aug 13, 2020

$37.27 (-0.96%)

Earnings

Q4 2022 Accolade Inc Earnings Call Transcript

Apr 28, 2022 / 08:30PM GMT

Release Date Price: $11.06 (-9.93%)

Transcript 10-K8-K

Operator

Good day, and thank you for standing by. Welcome to the Accolade Fourth Quarter 2022 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your first speaker today to Mr. Todd Friedman, Head of Investor Relations. Please go ahead.

Todd Friedman

Accolade, Inc. - SVP of IR

Thanks, operator. Welcome everyone to our fiscal fourth quarter earnings call. With me on the call today are our Chief Executive Officer, Rajeev Singh and our Chief Financial Officer, Steve Barnes. Shantanu Nundy, our Chief Medical Officer will join for the question-and-answer portion of the call.

Before turning the call over to Rajeev, please note that we will be discussing certain non-GAAP financial measures that we believe are important when evaluating Accolade's performance. Details on the relationship between these non-GAAP measures to their most comparable GAAP measures and the reconciliations thereof can be found in the press release that is

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.